Get a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORECreative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE Highlights
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Cancer can evade immune detection by "closing" T cells through an inhibitory ligand-receptor interaction at an immune checkpoint. Destruction of these interacting antibodies or recombinant forms of receptors or ligands can stimulate very potent anti-tumor responses. Recent discoveries in this field have significantly expanded the range of treatments developed for patients, with the ultimate goal of giving long-term immunity to cancer. Therefore, identifying new immunotherapeutic targets provides important business value to our customers.
Since many important immune checkpoint interactions have not been fully characterized, we continue to work extensively in this area. To do this, Creative Biolabs'unique and highly sensitive Surfarray™ cell microarray technology is optimized for the identification of novel immune checkpoints.
Extremely High Success Rate
To date, Creative Biolabs has accumulated extensive phenotypic molecular screening experience through several projects, including projects on "difficult" molecules. We have screened for specific, repeatable molecules with a success rate of more than 50% due to the extensive collection of membrane proteins expressed by human cells.
High Specificity
Surfarray™'s low false positive rate ensures that months or years of research are not wasted to chase dead ends when verifying potential target hits. Immune Checkpoints Discovery using Surfarray™ cell microarray technology typically produces one or two repeatable hits that are specific to the test molecule and typically represent the primary receptor target and its different isoforms.
Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in CAR-T cell therapy. We utilize unrivaled, proprietary drug design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.
For more detailed information, please feel free to contact us or directly send us an inquiry.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
